Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Instagram Outage Disrupts Thousands of U.S. Users 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
SAN FRANCISCO, May 03, 2017 -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced that it will report first quarter financial results on Tuesday, May 9, 2017, after market close, and will host a conference call to discuss financial results and provide a business update at 4:30 p.m. ET (1:30 p.m. PT).
Audio Webcast
Interested parties may access a live audio webcast of the conference call via the investor section of the FibroGen website, www.fibrogen.com. It is recommended that listeners access the website 15 minutes prior to the start of the call to download and install any necessary audio software. A replay of the webcast will be available shortly after the call for a period of two weeks. To access the replay, please dial (888) 843-7419 (domestic) or (630) 652-3042 (international), and use passcode 44595888#.
Dial-In Information
Live (U.S./Canada): (888) 771-4371
Live (International): (847) 585-4405
Confirmation number: 44595888
About FibroGen
FibroGen, Inc., headquartered in San Francisco with subsidiary offices in Beijing and Shanghai, is a leading science-based biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics. The company applies its pioneering expertise in fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat (FG-4592), the company’s most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase 3 clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase 3 development for anemia in lower risk myelodysplastic syndromes (MDS). Pamrevlumab (FG-3019), a fully-human monoclonal antibody that inhibits the activity of connective tissue growth factor (CTGF), is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer, and Duchenne muscular dystrophy (DMD). FibroGen is also developing a biosynthetic cornea in China. For more information, please visit www.fibrogen.com.
Contact Karen L. Bergman Vice President, Investor Relations and Corporate Communications FibroGen, Inc. [email protected] (415) 978-1433
